Life Sciences

  • September 16, 2026

    Muscular Dystrophy Drug Co. Beats Investor Suit Over Risks

    A Massachusetts federal judge denied investors another chance to rework their suit accusing Sarepta Therapeutics and its executives of misleading the market about the safety and efficacy of their muscular dystrophy treatments, saying it fails to show they knew about issues with the products and trials when they made certain statements.

  • September 16, 2026

    EOFlow Says Fed. Circ. Right To Ax $59M Trade Secret Verdict

    EOFlow Co. Ltd. says the Federal Circuit shouldn't rethink a panel's decision allowing it to escape a $59.4 million trade secret judgment, saying insulin product developer Insulet Corp. is trying to dress up factual disputes as issues needing the full court's attention.

  • September 16, 2026

    Bristol-Myers Looks To Block Amgen's Cancer Biosimilar

    Bristol-Myers Squibb Co. has sued rival Amgen Inc., seeking a court order blocking the manufacture of a biosimilar to the cancer drug Opdivo while patent rights on the drug's makeup remain in force.

  • September 15, 2026

    Express Scripts Accused Of Shorting Independent Pharmacies

    A dozen independent Arkansas pharmacies on Tuesday hauled Express Scripts into Missouri state court, accusing the pharmacy benefit management giant of continuously shorting them on prescription reimbursements despite Arkansas' efforts to combat underpayments.

  • September 15, 2026

    Connecticut Wins Fight Over School Vaccine Exemptions

    Connecticut has won the dismissal of a challenge to its mandatory school vaccination laws, beating through both litigation and legislative amendments allegations by parents that the state's rollback of vaccine exemptions violated religious freedom statutes and the state and federal constitutions.

  • September 15, 2026

    Meet The Attys In The 340B Battle At 1st Circ.

    Gibson Dunn and Dunn Isaacson Rhee attorneys presented arguments Tuesday at the First Circuit over whether drug manufacturers can intervene in a challenge to a now-suspended drug rebate program for hospitals. Law360 profiles the attorneys.

  • September 15, 2026

    Mich. AG Says PBMs Put Opioid Profits Before Patient Safety

    Michigan Attorney General Dana Nessel has asked a federal court not to dismiss the state's lawsuit accusing pharmacy benefit managers including Express Scripts and Optum of abetting the opioid epidemic, arguing the PBMs are not passive administrators, but profit-driven architects of the crisis.

  • September 15, 2026

    Takeda Can't Decertify Amitiza Class After $885M Jury Loss

    A Massachusetts federal court refused Takeda's request to decertify a class of Amitiza buyers, after a jury awarded groups of purchasers a total of $885 million for claims that the drugmaker conspired to delay the launch of a rival generic version of the anti-constipation drug.

  • September 15, 2026

    7th Circ. Debates Federalism, Bad-Faith Prosecution Limits

    A case deemed moot by the Seventh Circuit nonetheless drew commentary Monday from several judges on the court, with four calling an injunction that blocked Florida from pursuing a state court suit over youth gender-affirming care a "grievous blow" to federalism, while others said federal intervention is a "constitutional safety valve" against bad-faith prosecutions.

  • September 15, 2026

    FDA Seeks Applications For Project To Speed Up Human Trials

    Federal regulators on Tuesday launched a pilot program that will pair pharmaceutical companies with research institutions in an effort to make it faster and easier to conduct clinical trials on humans in the United States.

  • September 15, 2026

    1st Circ. Suggests Appeal In Drug Rebate Case May Be Moot

    A First Circuit panel raised mootness concerns as it heard arguments Tuesday from drug companies appealing a ruling that prevented them from intervening in a now-dismissed case to defend a rebate model for a federal drug-pricing program. 

  • September 15, 2026

    Insurers Can't Nix $195M Opioid Coverage Bid, Trustee Says

    Chubb, Liberty Mutual and Lloyd's of London units and other insurers can't get off the hook for covering the remainder of third-party payor opioid lawsuits against Endo International, a representative for a trust of the bankrupt pharmaceutical company told a Pennsylvania federal court.

  • September 15, 2026

    ITC To Eye Part Of Judge's Decision In Medical Dilation Row

    The full U.S. International Trade Commission is set to look at parts of an agency judge's ruling in favor of medical technology company Stryker Corp. in a fight against imports it said infringed its patents on balloon dilation products used in ear, nose and throat procedures.

  • September 15, 2026

    Trade Court Orders Better Explanation For Indian Glycine Rate

    The U.S. Department of Commerce must give a better explanation for why it chose to hit an Indian exporter of glycine with an antidumping duty rate it reached using a different calculation method than expected, the U.S. Court of International Trade ruled.

  • September 15, 2026

    Cooley, Latham Prep Electra Therapeutics' $325M IPO Plan

    Biotechnology firm Electra Therapeutics plans to make its public debut this week through an estimated $325 million initial public offering steered by Cooley LLP and Latham & Watkins LLP.

  • September 14, 2026

    Nektar 'Desperate' To Develop Rezpeg, Lilly Exec Tells Jury

    An Eli Lilly executive told a California federal jury on Monday in Nektar's $1 billion breach of contract suit against the pharma giant that his handwritten note from a meeting with Eli Lilly's CEO about Nektar being "desperate" was about the struggling company's need for its autoimmune-disease drug Rezpeg to succeed.

  • September 14, 2026

    Albertsons Owes $2.2B For Opioids, Wash. Says As Trial Ends

    Albertsons should pay $2.2 billion to address opioid-related harms in Washington, attorneys for the state argued at the close of a two-month bench trial Monday in contending that the pharmacy failed for years to appropriately identify and review suspicious prescriptions that fueled the state's overdose crisis.

  • September 14, 2026

    Motor Vehicles Lead Product Liability Litigation, Report Says

    An overall rise in recalls of motor vehicles tracks with an increase of product liability lawsuits over autos in recent years, as motor vehicle lawsuits made up half of all product liability lawsuits outside multidistrict litigation filed in 2025, according to a new report by Lex Machina.

  • September 14, 2026

    Cancer Detection Biotech Lodges Patent Suit Against Rival

    The company behind the colorectal cancer blood test Colvera has hit biotechnology company Grail Inc. with a lawsuit in Delaware federal court claiming the latter's Galleri test infringes a pair of patents.

  • September 14, 2026

    Eli Lilly's $200M Fraud Suit Is Still Defective, Church Cos. Say

    Companies affiliated with the Church of God in Christ urged a Florida federal judge to dismiss Eli Lilly's amended lawsuit alleging a $200 million-plus fraud scheme to resell the Trulicity diabetes drug on the secondary market, saying the latest complaint still lacks specificity despite including more claims. 

  • September 14, 2026

    Ex-Perrigo VP Escapes Some Price-Fixing Claims From AGs

    A Connecticut federal judge has tossed most of the claims against a former Perrigo executive in sprawling generic-drug price-fixing litigation brought by state enforcers, holding there is insufficient evidence he entered into antitrust conspiracies related to more than a dozen dermatological drugs, but teeing up a handful of other claims for trial.

  • September 14, 2026

    NY Village Can Pursue PFAS Claims Against Local Cos.

    A New York federal judge won't let a group of manufacturing and industrial companies out of a suit by the Village of Nyack alleging they contaminated the water supply with so-called forever chemicals, saying the allegations in the complaint make a plausible claim under state and federal environmental law.

  • September 14, 2026

    Feds Want Justices To Skip Google 'Settled Expectations' Row

    The federal government is telling the U.S. Supreme Court that Google didn't meet the appropriate standard to get the Federal Circuit to look at the company's challenge to the U.S. Patent and Trademark Office's policy of using the age of patents as a reason not to review them.

  • September 14, 2026

    Former Trump Assistant To Co-Lead Covington Policy Practice

    Covington & Burling LLP said Monday the firm has hired a former assistant to President Donald Trump, who served in the president's first administration as director of the Domestic Policy Council and most recently owned a federal consulting business in Washington, D.C.

  • September 14, 2026

    Abbott To Pay $385M To End FCA Claims Over Infant Formula

    The U.S. Department of Justice on Monday said that Abbott Laboratories has agreed to pay nearly $385 million to end False Claims Act allegations over the manufacture of contaminated infant formula at locations in Michigan and Arizona.

Expert Analysis

  • AG Watch: Oregon's Strategic Civil Enforcement Approach

    Author Photo

    Oregon Attorney General Dan Rayfield’s recent antitrust litigation activity and proposed staffing increase are the latest in a series of structural and policy changes that signal that the state Department of Justice is taking a more aggressive approach to civil enforcement, says Keturah Taylor at Cozen O'Connor.

  • How Nasdaq's 23/5 Rule Will Alter Public Offering Strategies

    Author Photo

    The U.S. Securities and Exchange Commission's recent approval of Nasdaq's proposal to extend trading hours to 23 hours a day, five days a week, may reshape how certain public offerings are executed, particularly for confidentially marketed public offerings, say attorneys at Faegre Drinker.

  • The Paradoxical Duty To Adopt AI When You Can't Bill For It

    Author Photo

    Both billing for hours saved using artificial intelligence and preserving billable time by not adopting AI may violate rules of professional conduct, but until bar associations' ethics rules catch up to this emerging economic dilemma, firms must decide how to adjust fee structures themselves, says Ines Lassalle at Peyrot & Associates.

  • Tips For Litigating Life Sciences Investigations At The ITC

    Author Photo

    The International Trade Commission may soon become a significant battleground for life sciences companies as global intellectual property and trade disputes continue, increasing the importance of learning the ITC's unique considerations and litigation strategies, say attorneys at Crowell & Moring.

  • Ch. 15 Ruling Is A Restructuring Blueprint For Cannabis Cos.

    Author Photo

    The recent Cannabist Chapter 15 recognition order is arguably the most significant cannabis bankruptcy development in U.S. history, providing a concrete and tested road map by which such companies with foreign parent structures can access the protective machinery of U.S. bankruptcy law, say attorneys at Saul Ewing.

  • Unsecured Synthetic Royalties May Be Returning

    Author Photo

    Recent royalty monetization deals mark a notable shift in a market that had largely moved away from unsecured synthetic royalty structures after a multiyear freeze triggered by the Mallinckrodt bankruptcy decision in 2022, which exposed a legal risk inherent to the structure, says Peter Schwartz at Covington.

  • Series

    Cow Horse Makes Me A Better Lawyer

    Author Photo

    Moving an unwilling 800-pound cow while riding a horse at high speed is exhilarating, a little unhinged and, at least for me, a surprisingly effective training ground for litigation — both demand focus, preparation over rigid planning and the willingness to act despite fear, says Ashley Zitrin at Glenn Agre.

  • Protecting AI-Driven Innovation In Life Sciences IP

    Author Photo

    Recent developments, including the U.S. Patent and Trademark Office's evolving inventorship standards, and the impact of artificial intelligence on the "person of ordinary skill in the art" standard demand that life sciences companies elevate AI patent strategy to a top priority, says Sandra Haberny at Quinn Emanuel.

  • What Prop 65 Listings For Welding Fumes, Drugs Mean For Cos.

    Author Photo

    With California poised to add welding chemicals and three medications to its list of known carcinogens under Proposition 65, businesses must assess risks from nontraditional pharmaceutical dispensing, occupational and environmental exposures to welding operations, and downstream exposures from the manufacture of both types of substances, says Gregory Berlin at Alston & Bird.

  • High Court's Hikma Decision Reshapes 'Skinny Label' Suits

    Author Photo

    The U.S. Supreme Court's decision in Hikma v. Amarin marks a significant victory for generic drug manufacturers, but rather than putting an end to so-called skinny label inducement claims, it narrows and refocuses them, say attorneys at Sterne Kessler.

  • Virginia's Cannabis Retail Veto Leaves Industry In Legal Limbo

    Author Photo

    Virginia Gov. Abigail Spanberger's recent veto of legislation that would have established a regulated retail cannabis framework halts momentum built by the General Assembly, but it also sends important signals about what a future regulatory framework must address to survive, says Charles Slemp at Cozen.

  • Checking For AI Errors Is Now A Two-Way Street

    Author Photo

    A handful of recent federal and state cases demonstrate the importance of checking for errors generated by artificial intelligence not only in your own court submissions, but also your opponent's, as well as when catching opposing counsel's AI mistakes could result in an award for attorney fees, says Tamara Barago at Hollingsworth.

  • Series

    The Biz Court Digest: Shoring Up Corporate Law In Maryland

    Author Photo

    Launched more than 20 years ago to improve complex corporate adjudication, Maryland's Business and Technology Case Management Program has been a solid success in some areas, but there always is room for improvement, says Bill Krulak at Miles & Stockbridge.

  • State Enviro Agencies Give Cosmetics Regulation A Makeover

    Author Photo

    As state oversight of cosmetics rapidly expands, the new statutes and regulations governing these products are being implemented by environmental agencies rather than consumer product regulators, requiring manufacturers, distributors and retailers to reevaluate their supply chains and procedures, say attorneys at Baker Botts.

  • FDA's Chemical Review Process Heats Up Food Industry Risk

    Author Photo

    The U.S. Food and Drug Administration's newly announced process for postmarket assessment of food additives signals a significant shift away from historically limited oversight, introducing both strategic opportunities and material risks for food manufacturers, ingredient suppliers and others in the food supply chain, say attorneys at Morgan Lewis.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.